Skip to content

Study · Not a test of the peptide alone · 2022

4 results

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.

Dardano A, Aragona M, Daniele G, Miccoli R, Del Prato S

Frontiers in endocrinology28 Feb 2022Cited by 3 (Europe PMC)

PMID35295985 (opens in a new tab)PMCIDPMC8918572 (opens in a new tab)DOI10.3389/fendo.2022.847778 (opens in a new tab)PepBankPUB-35295985
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundType 2 diabetes (T2D) is a common comorbidity in people living with HIV (PLWH). Anti-hyperglycemic treatment in PLWH is still a challenge, and no randomized controlled studies using new glucose-lowering agents are currently available.Case descriptionA 55-year-old-women was admitted to our Diabetes Unit because of hyperosmolar hyperglycemic state (HHS) and sepsis. The medical history included HIV infection and insulin-treated diabetes. On clinical examination, the lady appeared dehydrated with dry buccal mucosa, tachycardia, altered mental status, genital infection, and fever. On admission, plasma glucose was 54.5 mmol/L, HbA1c 155 mmol/mol, osmolarity 389.4 mOsm/kg, bicarbonate 24.6 mmol/L with no detectable serum ketones. The patient was treated with i.v. fluid and insulin, and antibiotic therapy commenced. Upon HHS and sepsis resolution, a basal-bolus insulin therapy was implemented that was followed by significant improvement of daily glucose profiles and progressive reduction of insulin requirement until complete discontinuation. A low dose of metformin plus linagliptin was started. Since a severe atherosclerotic disease was diagnosed, a GLP-1 receptor agonist, dulaglutide, was added to metformin upon linagliptin withdrawal with maintenance of good glycemic control, treatment adherence and amelioration of quality of life and no side effects.ConclusionThis case suggests that GLP-1 receptor agonist therapy may be effective and safe for treatment of T2D with high cardiovascular risk in PLWH, supporting the need of clinical trials directly assessing the safety and the efficacy of GLP-1 receptor agonist in these individuals.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a woman with HIV and diabetes, dulaglutide plus metformin after linagliptin withdrawal maintained good glycemic control.

    In plain wordsIn one woman, dulaglutide plus metformin maintained good blood sugar control after linagliptin stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedGlycemic control
    Study

    n = 1

    Comparator
    Before regimen change
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Since a severe atherosclerotic disease was diagnosed, a GLP-1 receptor agonist, dulaglutide, was added to metformin upon linagliptin withdrawal with maintenance of good glycemic control, treatment adherence and amelioration of quality of life and no side effects.
    2 context sentences
    Summary · context
    A 55-year-old-women was admitted to our Diabetes Unit because of hyperosmolar hyperglycemic state (HHS) and sepsis.
    Summary · context
    The medical history included HIV infection and insulin-treated diabetes.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesOther

    In a woman with HIV and diabetes, treatment adherence persisted with dulaglutide plus metformin after linagliptin withdrawal.

    In plain wordsIn one woman, treatment adherence continued with dulaglutide plus metformin after linagliptin stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedTreatment adherence
    Study

    n = 1

    Comparator
    Before regimen change
    Outcome group
    Treatment adherence and retention · Whole body

    Source sentences

    Summary
    Since a severe atherosclerotic disease was diagnosed, a GLP-1 receptor agonist, dulaglutide, was added to metformin upon linagliptin withdrawal with maintenance of good glycemic control, treatment adherence and amelioration of quality of life and no side effects.
    2 context sentences
    Summary · context
    A 55-year-old-women was admitted to our Diabetes Unit because of hyperosmolar hyperglycemic state (HHS) and sepsis.
    Summary · context
    The medical history included HIV infection and insulin-treated diabetes.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a woman with HIV and diabetes, quality of life improved with dulaglutide plus metformin after linagliptin withdrawal.

    In plain wordsIn one woman, quality of life improved with dulaglutide plus metformin after linagliptin stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseQuality of life
    Study

    n = 1

    Comparator
    Before regimen change
    Outcome group
    Quality of life · Whole body

    Source sentences

    Summary
    Since a severe atherosclerotic disease was diagnosed, a GLP-1 receptor agonist, dulaglutide, was added to metformin upon linagliptin withdrawal with maintenance of good glycemic control, treatment adherence and amelioration of quality of life and no side effects.
    2 context sentences
    Summary · context
    A 55-year-old-women was admitted to our Diabetes Unit because of hyperosmolar hyperglycemic state (HHS) and sepsis.
    Summary · context
    The medical history included HIV infection and insulin-treated diabetes.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome

    In a woman with HIV and diabetes, no side effects were reported with dulaglutide plus metformin after linagliptin withdrawal.

    In plain wordsOne woman had no reported side effects with dulaglutide plus metformin after linagliptin stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSide effects
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Since a severe atherosclerotic disease was diagnosed, a GLP-1 receptor agonist, dulaglutide, was added to metformin upon linagliptin withdrawal with maintenance of good glycemic control, treatment adherence and amelioration of quality of life and no side effects.
    2 context sentences
    Summary · context
    A 55-year-old-women was admitted to our Diabetes Unit because of hyperosmolar hyperglycemic state (HHS) and sepsis.
    Summary · context
    The medical history included HIV infection and insulin-treated diabetes.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.